E-Aushadhi and Traceability: The Future of Ayurvedic Quality Control

The Technological Shift in AYUSH Regulation

Ayurvedic manufacturing in India is moving from paper files to a single digital system. This shift is reshaping how the government licenses, tracks, and verifies every AYUSH product on the market.

The Paradigm Shift: From Paper-Based Licensing to C-DAC's Digital Infrastructure

For decades, the Drugs and Cosmetics Act, 1940 governed the Ayurveda, Siddha, Unani, and Homoeopathy (ASU&H) sector through separate state licensing offices. Each state kept its own paper records.

This gap created real risks. Illicit manufacturers could exploit inconsistent state numbering systems, slip past pharmacovigilance (drug-safety) monitoring, and avoid accountability for adulterated products.

To close these gaps, the Ministry of AYUSH worked with the Central Drugs Standard Control Organization (CDSCO) to launch the e-Aushadhi portal. Built and maintained by the Centre for Development of Advanced Computing (C-DAC), e-Aushadhi is a web-based licensing and supply-chain platform that now anchors AYUSH regulation nationwide.

The portal connects every part of the system in one place:

• State Licensing Authorities (SLAs)
• State drug inspectors
• Analytical testing laboratories
• Pharmaceutical manufacturers

By linking these groups into one secure digital ecosystem, e-Aushadhi digitises the full lifecycle of a traditional medicine, from raw material to finished product.

Why the Government Built e-Aushadhi: Three Core Objectives

The rollout serves three connected goals:

• Stop adulteration and counterfeiting. Remove misbranded and fake traditional medicines from the legitimate retail supply chain.
• Standardise manufacturing quality. Enforce the Ayurvedic Pharmacopoeia of India (API) and Schedule T Good Manufacturing Practices (GMP) across every licensed facility.
• Match global pharma standards. Align Indian AYUSH manufacturing with international compliance benchmarks to make it easier for Indian brands to compete abroad.

The stakes are significant. India's Ayurvedic market is projected to grow from USD 10.6 billion in 2025 to USD 25.8 billion by 2035, a compound annual growth rate of 9.3%. Digital traceability directly supports this growth: it provides manufacturers with a faster, more reliable path to a Certificate of Pharmaceutical Product (WHO-COPP), the credential exporters need to sell AYUSH products internationally.

What is the e-Aushadhi portal?

The e-Aushadhi portal is a mandatory, centralised platform built by C-DAC for the Ministry of AYUSH. It manages licensing and supply-chain oversight for Ayurvedic, Siddha, Unani, and Homoeopathy manufacturers. The portal digitises manufacturing approvals, enforces regulatory compliance, and provides end-to-end cryptographic traceability, closing the door on counterfeit and adulterated products nationwide.

In short, e-Aushadhi turns a fragmented, paper-based licensing system into one verifiable digital record, giving Indian AYUSH manufacturers the traceability they need to build trust at home and open new markets abroad.

e-Aushadhi portal: the digital backbone of AYUSH manufacturing licenses

Form 24D vs Form 25E: what separates them

The perpetual-validity provision is a recent statutory shift. It removes the historical requirement for periodic manual renewals, and licensees keep their status active by maintaining GMP certification and filing annual self-compliance declarations through the portal itself.

How the e-Aushadhi workflow verifies a license application

The diagram above traces the six-stage path: a manufacturer submits site blueprints and staff credentials, the State Licensing Authority (SLA) checks those documents, the manufacturer links to an approved public testing laboratory, the SLA conducts a physical site inspection and GMP audit, the system issues the perpetual Form 25D or Form 25E license, and the entity enters the national track-and-trace ledger.

Premises requirements: area, layout and Schedule T rules

• Minimum operational area: 1,200 square feet for a single product category, on land zoned for industrial use
• Digitally verified site layouts and blueprints required at application stage
• Schedule T mandates independent space for four functions: raw material receipt, the manufacturing process area, the quality control section and finished goods storage
• Rasaushadhi (herbo-mineral formulations) manufacturers need a dedicated 150 square foot raw material store
• A furnace or Bhatti section (used for calcining heavy metals such as arsenic or mercury) needs a tin roof, proper ventilation and a specialised exhaust system to manage toxic fumes

Staff credentials: the portal cross-checks

• At least 2 registered medical practitioners holding a BAMS (Bachelor of Ayurvedic Medicine and Surgery) or BUMS (Bachelor of Unani Medicine and Surgery) degree
• At least 2 registered pharmacists
• All credentials verified digitally and in real time before the application proceeds

How public testing labs get linked to a manufacturer's dossier

An external public testing laboratory registers independently on the portal, submits its accreditation (commonly ISO 17025 or NABL), and receives SLA approval. Only then can the manufacturer digitally link that lab to their Form 24D or Form 25E dossier. This chain keeps every Certificate of Analysis (COA) tied to a verified, accountable lab, closing the door on forged testing data entering the supply chain.

The 2026 Legacy Module rollout: key dates

Every existing Form 25D or Form 25E holder had to upload their previously approved manual records into the Legacy Module: polyherbal formulations, historical GMP compliance certificates and past Form 48 approvals. SLAs then verified this legacy data, and that verification became a hard gate: a manufacturer needed SLA sign-off on legacy records before applying for new product approvals, requesting a WHO-COPP (Certificate of Pharmaceutical Product) for export, or generating new digital batch records.

The compliance load e-Aushadhi is built to ease

Industry audits point to steep numbers for small and mid-size AYUSH manufacturers: a typical MSME carries over 1,450 compliance obligations a year, spread across 59 types of inspectors, at a yearly cost between Rs 13 lakh and Rs 17 lakh. Among surveyed firms, 92% reported production delays tied to pharmacopeial monograph revisions, and 72% of firms needing GMP or GLP upgrades put the capital cost above Rs 2 crore. The portal functions as a Digital Public Infrastructure (DPI) intervention meant to centralise this burden, even though the initial migration phase itself demanded heavy lifting from manufacturers.

Ayush Drugs (Eleventh Amendment) Rules, 2026: S.P.C. Codes, QR Labelling, Microbiologist Rules & Shelf-Life Compliance

In July 2026, the Central Government notified the Ayush Drugs (Eleventh Amendment) Rules, 2026, via Gazette Notification G.S.R. 657(E). The amendment introduces a mandatory six-part Specific Product Code (S.P.C.) for every AYUSH formulation, permits QR-code and GTIN-based digital labelling under Rule 161, requires a qualified microbiologist at every manufacturing site under Rule 160B, and sets strict shelf-life limits under Rule 161B for products approved through accelerated stability studies.

Key takeaways:

• Every AYUSH product now needs a standardised six-component S.P.C. that doubles as its manufacturing license number
• Existing product codes must be reissued in the new S.P.C. format by July 24, 2028
• Manufacturers can now display full ingredient lists via QR code, GTIN, or barcode instead of squeezing them onto physical labels
• A qualified microbiologist must be present at every ASU manufacturing site
• Products approved on accelerated stability data get a maximum 1–2 year provisional shelf life and must follow up with real-time stability data

What Is the AYUSH Specific Product Code (S.P.C.) Under Rule 158B?

The Specific Product Code (S.P.C.) is a standardised, six-part alphanumeric identifier introduced by sub-rule (VII) inserted into Rule 158B of the Ayush Drugs (Eleventh Amendment) Rules, 2026. It functions as a cryptographic identifier that permanently binds every physical AYUSH product moving through the supply chain to its master digital dossier inside the e-Aushadhi database, ensuring absolute uniqueness across millions of distinct production batches.

The 6-Component Structure of the S.P.C. Code

Why the S.P.C. Also Functions as the Manufacturing License Number

The Eleventh Amendment's core legal mechanism is that it conflates the product identifier with the manufacturing authorisation itself. The State/UT code, license type, and license serial number embedded in the S.P.C. legally constitute the manufacturing license number, meaning generating or printing an S.P.C. is itself a declaration of holding a valid, SLA-verified Form 25D or 25E license. Fabricating these codes is therefore a direct violation of licensing law, subject to immediate prosecution.

"State/Union Territory code/ D or E (License or Loan license)/serial number of license in the product code shall be treated as manufacturing license number." — Gazette Notification G.S.R. 657(E)

Two-Year Transition Window: July 24, 2028 Deadline

The legislation provides a rigid two-year transitional window so the existing supply chain isn't disrupted overnight. Every existing product code across the Indian market must be systematically recalled and reissued to match the uniform S.P.C. pattern by July 24, 2028. Physical labels must reflect the new identifier using a specific mandatory phrase:

"The specific product code of the drug being preceded by the words 'specific product code or S.P.C.', which shall be printed or written within two years of the commencement of the Drugs (Eleventh Amendment) Rules, 2026." - Gazette Notification G.S.R. 657(E)

ADMA's Objection: Are Hydroalcoholic Extracts Really "Ayurvedic Drugs"?

Rule 158B's implementation has generated significant industry friction, particularly from the Ayurvedic Drug Manufacturers' Association (ADMA). ADMA has raised biochemical and philosophical objections to classifying all herbal extracts - specifically hydroalcoholic extracts - as Ayurvedic drugs under the new S.P.C. framework. Classical Ayurveda determines therapeutic value through rasa, guna, veerya, vipak, and prabhav (RGVV&P), using crude powders, decoctions, or aqueous extracts. ADMA argues hydroalcoholic extraction represents a fundamentally different chemistry that deviates from classical texts, and that products relying on modern solvent extraction should sit outside the strict domain of traditional Ayurveda rather than being granted a blanket S.P.C. under Patent and Proprietary (PP) classification.

Rule 161: QR Code and Digital Labelling Rules for AYUSH Packaging

Traditional polyherbal formulations are intrinsically complex - involving dozens of active botanical ingredients, intricate mineral excipients (Bhasmas), specific vehicles of administration (Anupana), and detailed contraindications. Standard packaging's spatial limits have historically forced manufacturers into microscopic, near-illegible ingredient lists, or reliance on separate paper package inserts that consumers easily lose or discard.

The Eleventh Amendment resolves this by amending Rule 161 to permit dynamic digital labelling. Under the newly inserted sub-rule 161(3A), the Ministry of AYUSH formally recognises the legal validity of digital markers as a labelling substitute:

"(3A) All the label information may also be displayed through QR code or..." - Gazette Notification G.S.R. 657(E)

When the full ingredient and excipient list is too extensive for the physical label, manufacturers can now legally display it via:

• Quick Response (QR) Code
• Global Trade Item Number (GTIN)
• Standard barcode

This resolves the packaging space constraint while creating a direct, scannable link between the consumer's smartphone and the e-Aushadhi track-and-trace cloud.

Rule 160B: Mandatory Microbiologist Qualifications at AYUSH Manufacturing Units

The 2026 amendments expanded Rule 160B - which governs the qualifications of technical personnel supervising ASU manufacturing operations - to mandate the continuous presence of a qualified microbiologist at the manufacturing site.

A microbiologist qualifies under Rule 160B if they hold:

• A bachelor's degree in microbiology plus at least 6 months of verified quality control experience, or
• A postgraduate degree in microbiology from a recognised university

This addresses a core risk in ASU manufacturing: because formulations rely heavily on raw, earth-derived botanical materials, they're highly susceptible to microbial contamination, heavy fungal loads, and toxic aflatoxin proliferation if improperly stored or processed. Mandatory microbiological oversight ensures continuous adherence to the microbial limits defined in the Ayurvedic Pharmacopoeia of India (API).

Rule 161B: Shelf-Life Rules for Accelerated Stability Studies

Rule 161B governs how a drug's shelf-life and expiration date are determined, mandating compliance with the stability study protocols in the API, Part I, Volume VIII - modernising the historical practice of estimating shelf-life from classical textual references.

Accelerated stability studies subject a drug to extreme temperature and humidity (typically 40°C ± 2°C / 75% RH ± 5% RH) to artificially speed up chemical degradation, allowing faster market approval. In exchange, the regulator caps the shelf-life that can be granted:

The catch: to keep market authorisation and S.P.C. status, the licensee must conduct and submit a full real-time stability study report (under standard atmospheric conditions) to the SLA within one year following the expiry of the provisional shelf-life granted on accelerated data. Failing to produce this real-time validation triggers immediate regulatory action and product recall.

Related FAQs

What does S.P.C. stand for in AYUSH regulations?

S.P.C. stands for Specific Product Code - a mandatory six-part alphanumeric identifier assigned to every AYUSH formulation under Rule 158B of the Ayush Drugs (Eleventh Amendment) Rules, 2026.

Is the S.P.C. the same as the manufacturing license number?

Yes. The State/UT code, license type, and license serial number embedded within the S.P.C. legally constitute the manufacturing license number under G.S.R. 657(E).

By when must manufacturers switch to the new S.P.C. format?

All existing product codes must be reissued in the new S.P.C. format by July 24, 2028, under the two-year transitional window.

Can AYUSH manufacturers show ingredient lists only through a QR code?

Yes. Under Rule 161(3A), manufacturers can display the full label information - including extensive ingredient and excipient lists - through a QR code, GTIN, or standard barcode when physical label space is insufficient.

What qualifications does a microbiologist need under Rule 160B?

Either a bachelor's degree in microbiology with at least 6 months of verified quality control experience, or a postgraduate degree in microbiology from a recognised university.

How much shelf-life can accelerated stability studies grant?

A maximum of 1 year based on a 3-month accelerated study, or a maximum of 2 years based on a 6-month accelerated study - both provisional, pending real-time stability data.

Cross-Sector Synergy: Connecting AYUSH Traceability to Allopathic Schedule H2

The digital overhaul of India's AYUSH sector through e-Aushadhi is not happening in isolation - it runs parallel to the national QR code traceability mandate for allopathic drugs under Schedule H2 of the Drugs Rules, 1945. As Indian consumers get used to scanning QR codes on vaccines, antibiotics, and cancer drugs to verify authenticity, that same expectation of digital transparency is now extending to traditional Ayurvedic medicines, and the S.P.C. and Rule 161 QR provisions ensure AYUSH products meet an equivalent standard.

Key takeaways:

• Schedule H2 traceability began in November 2022, covering the top 300 allopathic brands
• A June 22, 2026 notification - G.S.R. 506(E), the Drugs (Seventh Amendment) Rules, 2026 - pulled all vaccines, all antimicrobials, all narcotic and psychotropic drugs, and all anticancer drugs into Schedule H2
• The Schedule H2 QR code must carry nine data elements: unique product ID code, generic name, brand name, manufacturer name and address, batch number, manufacture date, expiry date, manufacturing licence number, and excipient details
• Compliance takes effect July 1, 2027 for vaccines, anticancer drugs, and NDPS narcotics/psychotropics, with antimicrobials given until July 1, 2028
• Rising consumer familiarity with allopathic QR scanning is pushing the same transparency expectation onto Ayurvedic and herbal products
• The AYUSH S.P.C. (Rule 158B) and QR labelling allowance (Rule 161) were designed to keep pace with this national standard

What Is Schedule H2 Under the Drugs Rules, 1945?

Schedule H2 is the framework governing QR code and barcode-based traceability for allopathic pharmaceuticals in India, spearheaded by the Ministry of Health and Family Welfare. In November 2022, the Central Government took the foundational step by notifying G.S.R. 823(E), formally inserting Schedule H2 into the Drugs Rules, 1945. This original framework mandated verifiable QR codes or barcodes on the primary packaging of the top 300 allopathic pharmaceutical brands circulating in the domestic market, as a direct defence against counterfeiting.

The June 2026 Expansion: G.S.R. 506(E) and the Drugs (Seventh Amendment) Rules, 2026

In June 2026, the Health Ministry executed a massive expansion of the Schedule H2 framework. The expansion was formalised through the Drugs (Seventh Amendment) Rules, 2026, notified via G.S.R. 506(E) dated June 22, 2026, following public consultation on draft rules published in October 2025. The amended provisions dictate that all vaccines, critical antimicrobials, anti-cancer medications, and narcotic and psychotropic drugs covered under the NDPS Act, 1985 must now bear a serialised QR code on their packaging.

What the Schedule H2 QR code must display when scanned:

These nine elements are the mandated fields for every Schedule H2 QR code under the June 2026 amendment.

Compliance timeline:

Antimicrobials were given the extended 2028 deadline, roughly a year longer than the other three categories.

Why Allopathic QR Standards Are Reshaping Consumer Expectations for AYUSH Products

This macroeconomic shift in allopathic pharmaceutical regulation exerts a profound, unavoidable influence on consumer expectations for traditional AYUSH medicines. As the Indian populace becomes rapidly conditioned to scanning critical allopathic medications - such as broad-spectrum antibiotics and oncology drugs - with their smartphones to verify authenticity, manufacturing origins, and exact shelf-life parameters, their baseline expectation for pharmaceutical transparency fundamentally alters. Consumers inevitably demand the same level of cryptographic transparency and digital accountability from their traditional herbal supplements and over-the-counter Ayurvedic remedies.

How AYUSH S.P.C. and Schedule H2 Align: One National Traceability Standard

The synchronous implementation of the S.P.C. pattern under Rule 158B and the digital QR code labelling allowances under Rule 161 ensures the traditional medicine sector does not suffer a technological deficit relative to allopathic drugs. By aligning AYUSH traceability protocols directly with the established Schedule H2 framework, the government guarantees an interoperable national standard — the data fields embedded within the S.P.C. and the digital label mirror the same category of critical data elements demanded under Schedule H2. Ayurvedic medicines are now subjected to the same rigorous, digitally verifiable supply chain standards as modern allopathic formulations, elevating the entire AYUSH sector's global credibility and signalling to international regulators that Indian traditional medicines are tracked, traced, and verified with the same cryptographic certainty as modern pharmaceuticals.

FAQs

What is Schedule H2 under the Drugs Rules, 1945?

Schedule H2 is a framework requiring specified allopathic drug formulations to carry a QR code or barcode on their packaging for authentication and traceability, first introduced via G.S.R. 823(E) in November 2022 for the top 300 pharmaceutical brands.

What drugs were added to Schedule H2 in 2026?

Vaccines, antimicrobials, anti-cancer medications, and narcotic and psychotropic drugs under the NDPS Act, 1985 were added to Schedule H2 through the Drugs (Seventh Amendment) Rules, 2026, notified via G.S.R. 506(E) on June 22, 2026.

What information does a Schedule H2 QR code contain?

Nine data elements: unique product ID code, generic name, brand name, manufacturer's name and address, batch number, manufacture date, expiry date, manufacturing licence number, and excipient details.

When do the expanded Schedule H2 rules take effect?

July 1, 2027 for vaccines, anticancer drugs, and NDPS narcotics/psychotropics; July 1, 2028 for antimicrobials.

How does AYUSH's S.P.C. system relate to Schedule H2?

Both systems serve the same national goal - supply chain transparency and counterfeit prevention - using QR-scannable digital identifiers that mirror each other's core data fields, ensuring AYUSH and allopathic products meet an equivalent traceability standard.

Consumer Verification Mechanics: The Smartphone User Journey

The final goal of the e-Aushadhi portal, the S.P.C. code, and the newer regulatory rules is simple: build a closed supply chain that protects the patient the moment they buy or take a medicine. A single QR code scan turns any patient, pharmacist, or drug inspector into an active check-point in national drug safety.

This matters because the risk is real. Roughly 1 in 10 medicines sold in low- and middle-income countries fail quality testing and turn out to be substandard or falsified. Verification tools like this QR system exist to close that gap at the exact point where a patient could be harmed.

Technological Execution: URI/GTIN Decoding, SSL API Calls, and C-DAC Server Queries

Verification relies on constant, real-time communication between the printed code on the bottle and the backend systems that store its record: the Drugs and Vaccine Distribution Management System (DVDMS) and e-Aushadhi.

Here's what happens during a single scan:

1. Scan. A consumer, a pharmacist at a primary health centre, or a state drug inspector scans the packaging's QR code using a smartphone camera or a dedicated regulatory app.
2. Decode. The scanner reads the embedded Uniform Resource Identifier (URI) or GTIN matrix inside the QR code.
3. Secure request. The decode triggers an Application Programming Interface (API) call, sent over an encrypted Secure Sockets Layer (SSL) connection.
4. Server check. The request reaches C-DAC's central servers, which host both the e-Aushadhi and DVDMS databases.
5. Match against records. The system checks the code against its master ledger of approved Form 25D/25E licenses and batch production records.
6. Instant response. Within milliseconds, the API sends a standardised data payload back to the user's screen.

The 8 Mandatory Data Points Revealed Upon Scanning

To protect patient safety and guarantee accountability, every valid scan must legally display eight specific data points. These mirror the same transparency rules already used for allopathic medicines under the Schedule H2 standard.

The European Union has required a two-dimensional barcode and an anti-tampering seal on prescription medicine packaging since February 2019, and the United States runs a comparable track-and-trace system under the Drug Supply Chain Security Act. e-Aushadhi brings Indian AYUSH products in line with that same global standard.

Preventing Counterfeits via DVDMS Multi-Tiered Node-to-Node Verification

Scanning at the point of sale catches problems late. The stronger safeguard happens earlier: the DVDMS tracks every product movement through the supply chain and flags anything unusual before it ever reaches a patient.

Digital Handshake Protocols: Manufacturer → Warehouse → Retailer

Every step of the supply chain confirms the product's identity before passing it forward:

• The licensed Form 25D manufacturer generates serialised QR codes based on their approved S.P.C. and logs batch volume and serial data into e-Aushadhi before the product leaves the factory.
• The product moves through District Drug Warehouses (DDW), wholesale distributors, and finally Primary Health Centres (PHC) or retail pharmacies.
• Each of these points must scan the product on both receipt and dispatch.

Autonomous Anomaly Detection: Preventing Code Duplication and Unregistered Batches

If someone tries to introduce counterfeit medicine using cloned or copied QR codes, the DVDMS system catches it through location and timing checks.

For example: if a specific S.P.C. serial number is scanned at a warehouse in Maharashtra, but the database already shows that same code was scanned and dispensed to a patient in Gujarat three days earlier, the system flags it as a duplicate immediately. The same happens if a batch of codes shows up with no matching origin log from a registered Form 25D manufacturer. The system treats these as illegitimate on sight.

Once flagged, the system responds automatically:

• Blocks the transaction
• Freezes the batch's digital movement
• Alerts the State Licensing Authority and regional drug inspectorate for a physical follow-up

If a counterfeit product somehow reaches a retail shelf, the next consumer scan will trigger a clear warning on-screen, such as "Product Not Found," "Invalid Batch," or "Counterfeit Warning," stopping the sale before the patient takes the medicine.

Together, these checks turn a single QR code into a full safety net: instant proof of authenticity for the patient, and an early warning system for regulators.

Frequently Asked Questions

Below are the most commonly searched questions about the e-Aushadhi portal, the Specific Product Code (S.P.C.), QR code verification, heavy metal limits, and the adulteration risks the 2026 regulatory overhaul was built to eliminate.

What is the e-Aushadhi portal and who is required to register on it?

The e-Aushadhi portal is a mandatory, centralised online supply chain management and licensing platform developed by the Centre for Development of Advanced Computing (C-DAC) for the Ministry of AYUSH. It is designed to digitise and track the entire lifecycle of traditional medicines, from raw material sourcing to the point of retail sale. By law, all entities involved in the commercial production and analysis of Ayurvedic, Siddha, Unani, and Homoeopathy (ASU&H) drugs must register on the portal. This includes in-house manufacturers holding Form 25D licenses, third-party loan licensees operating under Form 25E, and all external public analytical testing laboratories - which must hold relevant ISO 17025 / NABL accreditations - that provide Certificates of Analysis for these products.

What does the S.P.C. code on an Ayurvedic medicine bottle mean?

The Specific Product Code (S.P.C.) is a cryptographic, six-part alphanumeric identifier mandated by Rule 158B under the Ayush Drugs (Eleventh Amendment) Rules, 2026. It denotes the state or Union Territory code, the license type (D for in-house manufacturing or E for third-party loan licensing), the manufacturer's license serial number, the system of medicine (Classical or Patent and Proprietary/PP), the product's specific SKU serial number, and the year of approval. Legally, this uniform code inherently constitutes the manufacturing license number itself, ensuring the physical product is indelibly linked to its approved digital dossier within the e-Aushadhi database and preventing counterfeiting and unauthorised manufacturing.

How do I scan a QR code to verify if my Ayurvedic medicine is authentic?

Consumers, pharmacists, and inspectors can verify authenticity by scanning the QR code, GTIN, or barcode located on the primary or secondary packaging of the medicine using a standard smartphone camera or a designated regulatory mobile application. This scan decodes the embedded URI and executes a secure SSL API query against the C-DAC/DVDMS servers. If the product is compliant and legally registered, the screen instantly reveals eight mandatory data points: the unique S.P.C., the proper and generic name, the brand name, the manufacturer's verified address, the specific batch number, manufacturing and expiry dates (scientifically validated by Rule 161B real-time stability studies), the manufacturing license number, and the complete excipient and ingredient list.

What are the permissible heavy metal limits for Ayurvedic products under the API?

To prevent severe heavy metal toxicity resulting from environmental contamination or the improper calcination of herbo-mineral preparations (Bhasmas), the Ayurvedic Pharmacopoeia of India (API) establishes strict, legally binding maximum permissible limits. Measured in parts per million (ppm), these limits are: Lead (Pb) at 10.0 ppm, Arsenic (As) at 3.0 ppm, Mercury (Hg) at 1.0 ppm, and Cadmium (Cd) at 0.3 ppm. These thresholds are rigorously enforced through mandatory instrumental testing using technologies like Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and Atomic Absorption Spectroscopy (AAS) before a batch can be released for sale into the market.

How does e-Aushadhi prevent synthetic steroid adulteration in herbal remedies?

Historically, unorganised and unlicensed healers adulterated "herbal" powders with potent synthetic allopathic drugs - such as dexamethasone (corticosteroids), diclofenac (NSAIDs), or clonazepam (benzodiazepines) - to manufacture the illusion of rapid symptomatic relief. e-Aushadhi systematically prevents this by enforcing strict Schedule T GMP tracking and mandating that all batches undergo rigorous analytical testing before S.P.C. generation, including LC-MS/MS testing, which definitively detects complex synthetic molecules hidden within herbal matrices1. Furthermore, because every legal product is cryptographically tied to its manufacturer via the S.P.C. code, if a case of steroid-induced Cushing's syndrome or Drug-Induced Liver Injury (DILI) is reported to the NPvCC via the Ayush Suraksha portal, regulators can instantly trace the S.P.C. back to the exact manufacturing node, execute a nationwide batch freeze, and initiate immediate criminal prosecution.

What is the difference between a Form 25D license and a Form 25E loan license?

A Form 25D license is issued to a manufacturer who owns and operates an in-house Ayurvedic, Siddha, Unani, or Homoeopathy production facility, granted after the digital submission of Form 24D through the e-Aushadhi portal1. A Form 25E license, by contrast, is a loan license issued to an applicant who does not own manufacturing infrastructure but legally uses the licensed premises, equipment, and technical staff of an established third-party manufacturer, applied for via Form 25E. Under the modernised regulatory framework, both license types are now granted perpetual validity, removing the historical requirement for periodic renewal - provided the licensee actively maintains Schedule T GMP certification and submits mandatory annual self-compliance declarations through the digital portal.

What are the facility and staffing requirements for an Ayurvedic manufacturing license in India?

To obtain a manufacturing license on e-Aushadhi, an applicant's premises must meet a statutory minimum operational area of 1,200 square feet for a single product category, verified through digitally submitted site layouts and blueprints. Schedule T further mandates dedicated, independent spaces for raw material receipt, manufacturing, quality control, and finished goods storage; herbo-mineral (Rasaushadhi) production, for example, requires a dedicated 150-square-foot raw material store and a properly ventilated furnace or Bhatti section to safely manage toxic fumes from metal calcination. On the staffing side, every application must include the verified, registered details of at least two qualified medical practitioners holding a BAMS (Bachelor of Ayurvedic Medicine and Surgery) or BUMS (Bachelor of Unani Medicine and Surgery) degree along with at least two registered pharmacists, all cross-checked digitally by the portal before approval.

Why do Ayurvedic manufacturers now need a qualified microbiologist on-site?

The 2026 amendments expanded Rule 160B to mandate the continuous presence of a qualified microbiologist at every ASU&H manufacturing site, either a bachelor's degree holder in microbiology with at least six months of verified quality control experience, or a postgraduate degree holder from a recognised university. This requirement exists because Ayurvedic formulations rely heavily on raw, earth-derived botanical materials, which are highly susceptible to microbial contamination, fungal growth, and toxic aflatoxin proliferation if improperly stored or processed. Mandatory on-site microbiological oversight ensures continuous, real-time adherence to the microbial limits defined in the API.

How is the shelf life of an Ayurvedic medicine determined and validated?

Under Rule 161B, shelf-life claims must be backed by rigorous scientific stability data rather than classical textual estimates. Manufacturers seeking rapid market approval can use accelerated stability studies exposing the drug to extreme conditions of roughly 40°C ± 2°C and 75% RH ± 5% RH, but the shelf-life initially granted is capped: a maximum of one year based on a three-month accelerated study, and a maximum of two years based on a six-month study. To retain market authorisation and S.P.C. status beyond this provisional period, the licensee must also complete and submit a full real-time stability study, conducted under standard atmospheric conditions, to the State Licensing Authority within one year of the provisional shelf-life expiring; failing to do so triggers regulatory action and product recall.

Can Ayurvedic manufacturers list all ingredients via QR code instead of printing them on the label?

Yes. Traditional polyherbal formulations often contain dozens of botanical ingredients, mineral excipients (Bhasmas), and detailed contraindications that cannot fit legibly on small physical packaging. The Eleventh Amendment addresses this by inserting sub-rule 161(3A), which formally permits manufacturers to display the complete label information, including the full ingredient and excipient list through a QR code, GTIN, or barcode whenever physical label space is insufficient. This creates a direct, scannable link between the consumer's smartphone and the e-Aushadhi track-and-trace database, resolving packaging constraints while preserving full regulatory transparency.

How does AYUSH QR code traceability compare to Schedule H2 for allopathic medicines?

The AYUSH sector's S.P.C. and QR code framework under Rules 158B and 161 was deliberately aligned with Schedule H2, the traceability mandate the Ministry of Health and Family Welfare introduced for allopathic drugs via Gazette Notification G.S.R. 823(E) in November 2022. Schedule H2 initially covered the top 300 allopathic brands and was expanded in June 2026 to cover vaccines, critical antimicrobials, anti-cancer medications, and NDPS-controlled narcotics and psychotropics, each requiring a QR code that stores nine data elements. Because Indian consumers are increasingly conditioned to scan allopathic medicines for authenticity, the government aligned AYUSH traceability with the same standard so that Ayurvedic, Siddha, Unani, and Homoeopathy products meet an equivalent level of digital accountability and global credibility.

What laboratory tests confirm the safety and authenticity of Ayurvedic medicines?

Third-party laboratories registered on e-Aushadhi rely on four gold-standard instrumental methods to generate the data required for batch release. ICP-MS (Inductively Coupled Plasma Mass Spectrometry) detects trace heavy metals down to parts-per-trillion concentrations and is the definitive test for confirming that Bhasmas have been properly calcined1. AAS (Atomic Absorption Spectroscopy) is a cost-effective, API-mandated standard for routine heavy metal limit testing. HPTLC (High-Performance Thin-Layer Chromatography) generates a visual phytochemical "fingerprint" of a formulation and is the gold standard for confirming the correct botanical species was used1. LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry) is the only technique capable of definitively detecting trace pesticide residues, mycotoxins, and hidden synthetic pharmaceutical adulterants within complex herbal matrices. Results are compiled into a digital Certificate of Analysis (COA) that must be uploaded to e-Aushadhi and linked to the batch number before an S.P.C. QR code can be generated.

How widespread is adulteration in unregulated Ayurvedic and herbal products in India?

Pharmacovigilance and laboratory studies conducted by institutions including ICMR, AIIMS, and the Institute of Liver and Biliary Sciences (ILBS) have found that unregulated, unlicensed traditional medicine products carry a severe contamination burden. Up to 92% of sampled unregulated products exhibited some form of biological contamination or dangerous botanical substitution, and nearly 50% contained undeclared synthetic pharmaceutical agents or toxic levels of heavy metals. This adulteration is a leading contributor to Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI) cases in India, frequently resulting in critical care admission or the need for liver transplantation. e-Aushadhi's mandatory registration, S.P.C. tracking, and analytical testing requirements are designed to systematically shrink this unorganised, unaccountable market.

Why did Giloy (Tinospora cordifolia) cause liver injury cases, and how does e-Aushadhi help prevent this?

During the COVID-19 pandemic, a surge in demand for Tinospora cordifolia (Giloy) for its immunomodulatory properties coincided with clusters of patients developing severe liver dysfunction resembling autoimmune hepatitis. Subsequent investigation using HPTLC phytochemical analysis and DNA barcoding revealed that many of these hepatotoxicity cases were not caused by genuine Tinospora cordifolia at all, but by botanical misidentification: manufacturers and consumers had mistakenly sourced Tinospora crispa, a morphologically identical but intrinsically hepatotoxic lookalike species. This crisis is a central reason the API and e-Aushadhi framework mandate HPTLC fingerprinting before manufacturing, ensuring the correct, therapeutic botanical species is verified, and toxic lookalikes are screened out before a product ever reaches the S.P.C. and QR-code stage.

What was the e-Aushadhi Legacy Module, and what happened to manufacturers who missed the 2026 compliance deadline?

The Legacy Module was a mandatory data-migration mechanism activated by C-DAC on April 28, 2026, following a fresh, cryptographically secure re-registration requirement that began on April 16, 2026. Every existing Form 25D or Form 25E license holder was required to upload their previously approved manual records, formulations, GMP compliance certificates, and past approvals into the module, with State Licensing Authorities verifying this legacy data before any manufacturer could apply for new product approvals, request a WHO-COPP for export, or generate new digital batch records. After May 30, 2026, exclusive use of the e-Aushadhi portal became legally mandatory nationwide, permanently ending offline regulatory approvals, meaning any manufacturer who did not complete this migration lost the ability to obtain new approvals or generate valid S.P.C. codes through any offline channel.

Why is Rule 158B's classification of herbal extracts controversial?

The Ayurvedic Drug Manufacturers' Association (ADMA) has objected to Rule 158B's treatment of all herbal extracts, particularly hydroalcoholic extracts, as Ayurvedic drugs eligible only for an S.P.C. under the Patent and Proprietary (PP) classification. ADMA's argument rests on classical Ayurvedic pharmacology, which determines therapeutic value through rasa, guna, veerya, vipak, and prabhav (RGVV&P) using crude powders, decoctions, or aqueous extracts. The association contends that hydroalcoholic solvent extraction produces a fundamentally different chemical profile than classical preparation methods and represents a deviation that should arguably fall outside strict traditional Ayurveda classification, rather than being folded into the same S.P.C. framework by default.

How does e-Aushadhi detect counterfeit or duplicated QR codes in the supply chain?

The Drugs and Vaccine Distribution Management System (DVDMS) enforces a "digital handshake" protocol at every node of the supply chain from the Form 25D manufacturer's loading dock through district warehouses, wholesale distributors, and retail pharmacies, with each node required to scan the product on both receipt and dispatch. This creates an unbroken digital chain of custody that lets the system detect anomalies automatically. For example, if a specific S.P.C. serial number is scanned at a warehouse in one state days after the identical code was already scanned and dispensed to a patient in another state, the system immediately flags a duplication error. Codes that enter the supply chain without a corresponding origin log from a verified manufacturer are similarly flagged as illegitimate, triggering an automatic transaction block, digital batch freeze, and alert to the State Licensing Authority and regional drug inspectorate.